{"entity":{"id":"ohe-yuichiro","kind":"person","name":"Yuichiro Ohe","aka":[],"tldr":"Thoracic oncologist who leads NCC Hospital in Tokyo and has been a Japanese principal investigator on a generation of lung cancer trials.","summary":"Yuichiro Ohe is Director of the National Cancer Center Hospital in Tokyo and a thoracic oncologist. He has been a Japanese principal investigator on a generation of lung cancer trials, leading Japanese participation in EGFR, ALK and immunotherapy studies in non-small-cell and small-cell lung cancer. His publications include the FLAURA trial of osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. He directs the hospital while continuing work on lung cancer chemotherapy, targeted therapy and clinical trials.","asOf":"2026-09-08","links":[{"label":"National Cancer Center Hospital","url":"https://www.ncc.go.jp/en/ncch/index.html"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ohe%20Y%5BAuthor%5D%20National%20Cancer%20Center%20lung"}],"tags":[],"related":[],"cancers":["nsclc","sclc"],"sections":[],"technologies":[],"targets":[],"drugs":["osimertinib"],"companies":[],"institutions":["ncc-japan"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, National Cancer Center Hospital; thoracic oncology","institutionId":"ncc-japan","specialisms":["Lung cancer","Chemotherapy","Targeted therapy","Clinical trials"],"profiles":[{"label":"National Cancer Center Hospital","url":"https://www.ncc.go.jp/en/ncch/index.html"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ohe%20Y%5BAuthor%5D%20National%20Cancer%20Center%20lung"}],"papers":[{"title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer (FLAURA)","journal":"NEJM","year":2018,"doi":"10.1056/NEJMoa1713137"}]},"route":"/people/ohe-yuichiro/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"drug":[{"id":"osimertinib","kind":"drug","name":"Osimertinib","route":"/drugs/osimertinib/"}],"institution":[{"id":"jsmo","kind":"institution","name":"Japanese Society of Medical Oncology","route":"/institutions/jsmo/"},{"id":"ncc-japan","kind":"institution","name":"National Cancer Center Hospital","route":"/institutions/ncc-japan/"}],"paper":[{"id":"paper-flaura-nejm-2018","kind":"paper","name":"FLAURA: osimertinib as first treatment for EGFR-mutated lung cancer","route":"/key-papers/paper-flaura-nejm-2018/"}]}}